Share chart Geron Corporation
Main settings
Grade
Underestimation
Title | Value | Grade |
P/S | 28.53 | 1 |
P/BV | 7.82 | 1 |
P/E | 0 | 0 |
Efficiency
Title | Value | Grade |
ROA | -35.32 | 0 |
ROE | -66.09 | 0 |
ROIC | -59.63 | 0 |
Dividends
Title | Value | Grade |
Dividend yield | 0 | 0 |
DSI | 0 | 0 |
Average dividend growth | 0 | 0 |
Debt
Title | Value | Grade |
Debt/EBITDA | -0.786 | 10 |
Debt/Ratio | 0.2047 | 10 |
Debt/Equity | 1.12 | 8 |
Growth impulse
Title | Value | Grade |
Yield Revenue, % | 30332.41 | 10 |
Yield Ebitda, % | 106.74 | 10 |
Yield EPS, % | -1.7 | 0 |
Dividends
Prices
Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
Yesterday | 1.56 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
Week | 1.6 $ | 0 $ | 0 $ | -2.5 % | 0 % | 0 % |
Month | 1.48 $ | 0 $ | 0 $ | +5.41 % | 0 % | 0 % |
Three month | 1.39 $ | 1.18 $ | 1.62 $ | +12.23 % | 0 % | 0 % |
Half a year | 2.91 $ | 1.18 $ | 3.02 $ | -46.39 % | 0 % | 0 % |
Year | 4.66 $ | 1.18 $ | 4.78 $ | -66.52 % | 0 % | 0 % |
3 years | 2.54 $ | 1.18 $ | 5.09 $ | -38.58 % | 0 % | 0 % |
5 years | 1.82 $ | 0.99 $ | 5.09 $ | -14.29 % | 0 % | 0 % |
10 years | 0.8873 $ | 0.8873 $ | 6.38 $ | +175.81 % | 0 % | 0 % |
Year to date | 2.89 $ | 1.18 $ | 3.6 $ | -46.02 % | 0 % | 0 % |
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
Future Tech ETF | 0.27625 | 479.5 | 0.35 |
Principal Healthcare Innovators ETF | 0.27625 | -3.92 | 0.35 |
iShares Morningstar Small-Cap Growth ETF | 0.10126 | 570.49 | 0.06 |
iShares Morningstar Small-Cap ETF | 0.0513 | 301.34 | 0.25 |
0.18 | 336.85 | 0.25 |
---|
Similar companies
Company management
Head | Job title | Payment | Year of birth |
Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753.22k | 1964 (61 year) |
Ms. Shannon Odam | Senior VP & Chief People Officer | N/A | 1975 (50 years) |
Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/A | 1962 (63 years) |
Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1.53M | 1951 (74 years) |
Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/A | |
Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/A | 1983 (42 years) |
Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | N/A | 1967 (58 years) |
Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 847.2k | 1964 (61 year) |
Mr. Scott Samuels | Executive VP, Chief Legal Officer & Secretary | ||
Mr. James Ziegler M.B.A. | Executive VP & Chief Commercial Officer |
About company
Website: http://www.geron.com
About Geron Corporation
Корпорация "Герон", клиническая биофармацевтическая компания на поздней стадии, специализируется на разработке и коммерциализации методов лечения гематологических миелоидных злокачественных новообразований. Он обладает правами на иметелстат, ингибитор теломеразы в клинических испытаниях фазы 2F3, который ингибирует неконтролируемую пролиферацию злокачественных клеток-предшественников при гематологических миелоидных злокачественных опухолях, чтобы уменьшить дисфункциональную продукцию клеток крови и обеспечить восстановление нормальной продукции клеток крови. Компания была основана в 1990 году со штаб-квартирой в Менло-Парке, штат Калифорния.